Healthcare

Alterity Therapeutics has been listed on the ASX since March 2000 and remains pre-revenue. Its lead candidate, ATH434, targets the underlying pathology of multiple system atrophy and related Parkinsonian disorders. Behind it sits what the company calls a broad drug discovery platform generating patentable …

Bubs Australia is an infant nutritionBusinessfounded in 2006 and headquartered at Dandenong South in Victoria. It markets what it describes as clean nutrition for the first 1,000 days of life, with a range spanning A2 beta-casein protein formula, organic grass-fed cow milk formula, goat …

Recce Pharmaceuticals Ltd (ASX:RCE) is moving its lead anti-infective programme into a more comparative phase of clinical testing. In August 2026, a Human Research Ethics Committee approved an amendment adding a randomised, active-controlled, non-inferiority arm to the Australian Phase 3 trial of R327G Topical …

BlinkLab develops artificial-intelligence-driven, smartphone-based diagnostic technology for neurodevelopmental conditions. The platform applies reflex-based measures that the company says reduce reliance on observation-based assessment alone, and is designed for administration at home rather than only in a clinic.

Lumos Diagnostics Holdings Limited (ASX:LDX) develops and manufactures point-of-care diagnostic tests and also provides diagnostic development services. FebriDx is its lead commercial product and is designed to help distinguish bacterial from viral acute respiratory infection at the point of care.

Saluda Medical, Inc. (ASX:SLD) develops closed-loop spinal cord stimulation technology for chronic pain. Its Evoke system measures neural responses to stimulation and adjusts therapy in real time, with commercial activity concentrated in the United States and selected international markets.

Austco Healthcare Limited (ASX:AHC) released its FY2026 result in August 2026. Revenue was A$94.2 million, EBITDA was A$14.9 million and net profit after tax was A$9.0 million for the year ended 30 June 2026.